Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene

Cancer Research

Volumn 60, Issue 4, 2000, Pages 1035-1042

  Chen, Chien Hung ^a,d   Wang, Tian Li ^a   Hung, Chien Fu ^a   Yang, Yanqin ^a   Young, Richard A ^b,c   Pardoll, Drew M ^a   Wu, T C ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 70;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; GENE FREQUENCY; GENE FUSION; GENE THERAPY; GENETIC LINKAGE; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; BACTERIAL PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; HSP70 HEAT-SHOCK PROTEINS; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; VACCINATION; VACCINES, DNA;

EID: 0034652784     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Pardoll, D. M., and Beckerleg, A. M. Exposing the immunology of naked DNA vaccines. Immunity, 3: 165-169, 1995.
2. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A. DNA vaccines. Annu. Rev. Immunol., 15: 617-648, 1997.
3. Robinson, H. L., and Torres, C. A. DNA vaccines. Semin. Immunol, 9: 271-283, 1997.
4. Rodriguez, F., An, L. L., Harkins, S., Zhang, J., Yokoyama, M., Widera, G., Fuller, J. T., Kincaid, C., Campbell, I. L., and Whitton, J. L. DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination. J. Virol., 72: 5174-5181, 1998.
5. Tobery, T. W., and Siliciano, R. F. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in nivo after immunization. J. Exp. Med., 185: 909-920, 1997.
6. Boyle, J. S., Brady, J. L., and Lew, A. M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction, Nature (Lond.). 392: 408-411, 1998.
7. Biragyn, A., Tani, K., Grimm, M. C., Weeks, S., and Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol., 17: 253-258, 1999.
8. King, C. A., Spellerberg, M. B., Zhu, D., Rice, J., Sahota, S. S., Thompsett, A. R., Hamblin, T. J., Radl, J., and Stevenson, F. K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med., 4: 1281-1286, 1998.
9. Weiss, W. R., Ishii, K. J., Hedstrom, R. C., Sedegah, M., Ichino, M., Barnhart, K., Klinman, D. M., and Hoffman, S. L. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol., 161: 2325-2332, 1998.
10. Chow, Y. H., Chiang, B. L., Lee. Y. L., Chi, W. K., Lin, W. C., Chen, Y. T., and Tao, M. H. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol., 160: 1320-1329, 1998.
11. Corr, M., Tighe, H., Lee, D., Dudler, J., Trieu, M, Brinson, D. C., and Carson, D. A. Costimulation provided by DNA immunization enhances antitumor immunity. J. Immunol., 159: 4999-5004, 1997.
12. Klinman, D. M., Yamshchikov, G., and Ishigatsubo, Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines J. Immunol., 158: 3635-3639, 1997.
13. Srivastava, P. K., and Das, M. R. The serologically unique cell surface antigen of Zajdela ascitic hepaloma is also its tumor-associated transplantation antigen. Int. J. Cancer, 33: 417-422, 1984.
14. Srivastava, P. K., DeLeo, A. B., and Old, L. J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA, 83: 3407-3411, 1986.
15. Udono, H., and Srivastava, P. K. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J. Immunol., 152: 5398-5403, 1994.
16. Blachere, N. E., Udono, H., Janetzki, S., Li, Z., Heike, M., and Srivastava, P. K. Heat shock protein vaccines against cancer. J. Immunother., 14: 352-356, 1993.
17. Udono, H., Levey, D. L., and Srivastava, P. K. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci., 91: 3077-3081, 1994.
18. Tamura, Y., Peng, P., Liu, K., Daou, M., and Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (Washington DC), 278: 117-120, 1997.
19. Janetzki, S., Blachere, N. E., and Srivastava, P. K. Generation of tumor-specific cytotoxic T lymphocytes and memory T cells by immunization with tumor-derived heat shock protein gp96. J. Immunother., 21: 269-276, 1998.
20. Heikerna, A., Agsteribbe, E., Wilschut, J., and Huckriede, A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett., 57: 69-74, 1997.
21. Suto, R., and Srivastava, P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Washington DC), 269: 1585-1588, 1995.
22. Ciupitu, A. M., Petersson, M., O'Donnell, C. L., Williams, K., Jindal, S., Kiessling, R., and Welsh, R. M. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocyte. J. Exp. Med., 187: 685-691, 1998.
23. Blachere, N. E., Li, Z., Chandawarkar, R. Y., Suto, R., Jaikaria, N. S., Basu, S., Udono, H., and Srivastava, P. K. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med., 186: 1315-1322, 1997.
24. Suzue, K., and Young, R. A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol., 156: 873-879, 1996.
25. Suzue, K., Zhou, X., Eisen, H. N., and Young, R. A. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci., 94: 13146-13151, 1997.
26. Przepiorka, D., and Srivastava, P. K. Heat shock protein-peptide complexes as immunotherapy for human cancer. Mol. Med. Today, 4: 478-484, 1998.
27. Srivastava, P. K., Menoret, A., Basu, S., Binder, R. J., and McQuade, K. L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity, 8: 657-665, 1998.
28. Lin, K-Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, T., Pardoll, D. M., and Wu, T-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996
29. Miyahira, Y., Murata, K., Rodriguez, D., Rodriguez, J. R., Esteban, M., Rodrigues, M. M., and Zavala, F. Quantification of antigen specific CD8+ T cells using an ELISPOT assay. J. Immunol. Methods, 181: 45-54, 1995.
30. Murali-Krishna, K., Altman, J. D., Suresh, M., Sourdive, D. J., Zajac, A. J., Miller, J. D., Slansky, J., and Ahmed, R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity, 8: 177-187, 1998.
31. Feltkamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de, J. B., Drijfhout, J. W., ter, S. J., Melief, C. J., and Kast, W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
32. Tindle, R. W., Fernando, G. J., Sterling, J. C., and Frazer, I. H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc. Natl. Acad. Sci. USA, 88: 5887-5891, 1991.
33. Wu, T. C., Guarnieri, F. G.. Staveley, O. C. K. F., Viscidi, R. P., Levitsky, H, I., Hedrick, L., Cho, K. R., August, J. T., and Pardoll, D. M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA, 92: 11671-11675, 1995.
34. Ji, H., Wang, T-L., Chen, C-H., Hung, C-F., Pai, S., Lin, K-Y., Kurman, R. J., Pardoll, D. M., and Wu, T-C. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors. Hum. Gene Ther., 10: 2727-2740, 1999.
35. Dialynas, D. P., Quan, Z. S., Wall, K. A., Pierres, A., Quintans, J., Loken, M. R., Pierres, M., and Fitch, F. W. Characterization of the murine T cell surface molecule, designated L3T4. identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J. Immunol., 131: 2445-2451, 1983.
36. Sarmiento, M., Glasebrook, A. L., and Fitch, F. W. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J. Immunol., 125: 2665-2672, 1980.
37. Koo, G. C., Dumont, F. J., Tult, M., Hackett, J., Jr., and Kumar, V. The NK-1.1(-) mouse: a model to study differentiation of murine NK cells. J. Immunol., 137: 3742-3747, 1986.
38. Melief, C. J., and Kast, W. M. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev., 145: 167-177, 1995.
39. Alexander, J., Fikes, J., Hoffman, S., Franke, E., Sacci, J., Appella, E., Chisari, F. V., Guidotti, L. G., Chesnut, R. W., Livingston, B., and Sette, A. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunol. Res., 18: 79-92, 1998.
40. Murray, P. J., and Young, R. A. Stress and immunological recognition in host-pathogen interactions. J. Bacteriol., 174: 4193-4196, 1992.
41. Del Giudice. G. Hsp70: a carrier molecule with built-in adjuvanticity, Experientia, 50: 1061-1066, 1994.
42. Breloer, M., Fleischer, B., and von Bonin, A. In vivo and in vitro activation of T cells after administration of Ag-negative heat shock proteins. J. Immunol., 162: 3141-3147, 1999.
43. Chen, W., Syldath, U., Bellmann, K., Burkart, V., and Kolb, H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J. Immunol., 162: 3212-3219, 1999.
44. Wei, Y., Zhao, X., Kariya, Y., Fukata, H., Teshigawara, K., and Uchida, A. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res., 56: 1104-1110, 1996.
45. Laad, A. D., Thomas, M. L., Fakih, A. R., and Chiplunkar, S. V. Human γδ T cells recognize heat shock protein-60 on oral tumor cells. Int. J. Cancer, 80: 709-714, 1999.
46. Nichols, W. W., Ledwith, B. J., Manam, S. V., and Troilo, P. J. Potential DNA vaccine integration into host cell genome. Ann. NY Acad. Sci., 772: 30-39, 1995.
47. Lukas, J., Muller, H., Bartkova, J., Spitkovsky, D., Kjerulff, A. A., Jansen, D. P., Strauss, M., and Bartek, J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J. Cell Biol., 125: 625-638, 1994.
48. Pilon, M., and Schekman, R. Protein translocation: how Hsp70 pulls it off. Cell, 97: 679-682, 1999.
49. Srivastava, P. K., and Udono, H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol., 6: 728-732, 1994.
50. Srivastava, P. K., Udono, H., Blachere, N. E., and Li, Z. Heat shock proteins transfer peptides during antigen processing and CTL priming, Immunogenetics, 39: 93-98, 1994.
51. Arnold-Schild, D., Hanau, D., Spehner, D., Schmid, C., Rammensee, H. G., de la Salle, H., and Schild, H. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol., 162: 3757-3760, 1999.
52. Fujihara, S. M., and Nadler, S. G. Intranuclear targeted delivery of functional NF-κB by 70 kDa heat shock protein. EMBO J., 18: 411-419, 1999.
53. Porgador, A., Irvine, K. R., Iwasaki, A., Barber, B. H., Restifu, N. P., and Germain, R. N, Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med., 188: 1075-1082, 1998.
54. Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., and Stockinger, B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med., 189: 169-178, 1999.
55. Barrios, C., Georgopoulos, C., Lambert, P. H., and Del Giudice, G. Heat shock proteins as carrier molecules: in vivo helper effect mediated by Escherichia coli GroEL and DnaK proteins requires cross-linking with antigen. Clin. Exp. Immunol., 98: 229-233, 1994.
56. Anthony, L. S., Wu, H., Sweet, H., Turnnir, C., Boux, L. J., and Mizzen, L. A. Priming of CD8+ CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule. Vaccine, 17: 373-383, 1999.
57. Heck, D. V., Yee, C. L., Howley, P. M., and Munger, K. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses. Proc. Natl. Acad. Sci. USA, 89: 4442-4446, 1992.
58. Steinhoff, U., Brinkmann, V., Klemm, U., Aichele, P., Seiler, P., Brandt, U., Bland, P. W., Prinz, I., Zugel, U., and Kaufmann, S. H. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity, 11: 349-358, 1999.